SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 9:30 a.m. ET (6:30 a.m. PT) at the Lotte New York Palace in New York City. Management will also be available that day to meet with investors at the conference.
A live audio webcast of the presentation will be available in the Investors section of Harpoon’s website at www.harpoontx.com with an archived replay available for 30 days following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (TriTAC) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Harpoon Therapeutics, Inc.
Chief Financial Officer
Westwicke Partners, LLC.
Robert H. Uhl
Source: Harpoon Therapeutics